CHICAGO (EGMN) - Neoadjuvant treatment with the kinase inhibitor erlotinib might increase survival for patients with advanced bladder cancer, compared with traditional radical cystectomy alone, according to results of a pilot phase II study.Encouraging findings that were observed in patients with non-small cell lung and pancreatic cancers prompted researchers at the University of North Carolina at Chapel Hill to try erlotinib (Tarceva) prior to surgery in patients with invasive bladder cancer.In...